Who Paid My Doc
Abid Chaudhry
Podiatrist, Primary Podiatric Medicine Arleta, CA Doctor of Podiatric Medicine
NPI 1891875126 CMS profile 445683
9068 Woodman Ave, Arleta, CA 91331
General payments
$10,589
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$70,871
Through program year 2025, Abid Chaudhry of Arleta, CA is reported in the CMS Open Payments database as having received $10,589 across 133 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $70,871 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $496 | 10 | |
| 2024 | General | $1,101 | 5 | |
| 2023 | General | $2,757 | 23 | |
| 2022 | General | $1,634 | 21 | |
| 2021 | General | $2,667 | 44 | |
| 2020 | General | $470 | 14 | |
| 2019 | General | $1,464 | 16 |
Beside peers
- Abid Chaudhry
- Podiatrist, Primary Podiatric Medicine median
- Middle half of Podiatrist, Primary Podiatric Medicine
- National median
In program year 2025, general payments to Abid Chaudhry were reported at $496. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.
Show as a table
| Year | Abid Chaudhry | Podiatrist, Primary Podiatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,464 | $166 | $51–$513 | $163 |
| 2020 | $470 | $108 | $33–$249 | $114 |
| 2021 | $2,667 | $147 | $52–$377 | $132 |
| 2022 | $1,634 | $188 | $66–$551 | $149 |
| 2023 | $2,757 | $195 | $70–$509 | $160 |
| 2024 | $1,101 | $209 | $59–$508 | $164 |
| 2025 | $496 | $232 | $88–$586 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
131
Drug cost
$1,351
Branded share of claims
11.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 38 | $500 | |
| Dexamethasone | Generic | 26 | $297 | |
| Prednisone | Generic | 25 | $248 | |
| Doxycycline Hyclate | Generic | 12 | $128 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 15 | $122 | |
| Ciprofloxacin Hcl | Generic | 15 | $57 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 33 billing codesPaid by Medicare
$293,371
Medicare patients
2,085
Services billed
6,516
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 63% | |
| Diabetes | 61% | |
| Depression | 59% | |
| Alzheimer's or dementia | 50% | |
| Chronic kidney disease | 47% | |
| Ischemic heart disease | 41% | |
| Heart failure | 39% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 14 | 24 | $134 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
133 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Primary Podiatric Medicine in California
James Wang
Podiatrist, Primary Podiatric Medicine · Los Angeles, CA
Adam Shapiro
Podiatrist, Primary Podiatric Medicine · Upland, CA
Ali Ghorbanifarajzadeh
Podiatrist, Primary Podiatric Medicine · Bakersfield, CA
Matthew Garrison
Podiatrist, Primary Podiatric Medicine · Sacramento, CA
Linh Huynh
Podiatrist, Primary Podiatric Medicine · Turlock, CA
Yvette Canaba
Podiatrist, Primary Podiatric Medicine · Santee, CA
Related records
Podiatrist, Primary Podiatric Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Primary Podiatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.